首页> 外文期刊>brain pathology >Overexpression of the EGF Receptor andp53Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas
【24h】

Overexpression of the EGF Receptor andp53Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas

机译:EGF受体的过表达和p53突变在原发性和继发性胶质母细胞瘤的进化中是相互排斥的

获取原文
获取外文期刊封面目录资料

摘要

Glioblastoma multiforme, the most malignant human brain tumor, may developde nova(primary glioblastoma) or through progression from low‐grade or anaplastic astrocytoma (secondary glioblastoma). We present further evidence that primary and secondary glioblastomas constitute distinct disease entities which develop through the acquisition of different genetic alterations. We analyzedp53mutations, p53 protein accumulation and epidermal growth factor receptor (EGFR) overexpression in 49 biopsies classified as primary or secondary glioblastorna according to clinical and histopathologic criteria. Patients with primary glioblastoma were selected on the basis of a clinical history of less than 3 months and histopathologic features of glioblastoma at the first biopsy 119 cases; mean age, 55 years). The diagnosis of secondary glioblastomas required at least two biopsies and clinical as well as histologic evidence of progression from low grade or anaplastic astrocytoma (30 cases; mean age, 39 years). DNA sequence analysis showed thatp53mutations were rare in primary glioblastomas (11) while secondary glioblastomas had a high incidence ofp53mutations (67), of which 90 were already present in the first biopsy. The incidence of p53 protein accumulation (nuclear immunoreactivity to PAb 1801) was also lower in primary (37) than in secondary glioblastornas (97). In contrast, immunoreactivity for the EGF receptor prevailed in primary glioblastornas (63) but was rare in secondary glioblastornas (10). Only one out of 49 glioblastomas showed EGFR overexpression and ap53mutation. These data indicate that overexpression of the EGF receptor and mutations of thep53tumor suppressor gene are mutually exclusive events defining two different genetic pathways in the evolution of glioblastoma as the common phenotypic endpoin
机译:多形性胶质母细胞瘤是最恶性的人脑肿瘤,可能发展为新发性(原发性胶质母细胞瘤)或从低级别或间变性星形细胞瘤(继发性胶质母细胞瘤)进展而来。我们提供了进一步的证据表明,原发性和继发性胶质母细胞瘤构成了不同的疾病实体,这些疾病实体通过获得不同的基因改变而发展。我们根据临床和组织病理学标准分析了 49 例被归类为原发性或继发性胶质母细胞瘤的活检中的 dp53 突变、p53 蛋白积累和表皮生长因子受体 (EGFR) 过表达。原发性胶质母细胞瘤患者根据临床病史不足3个月和首次活检时胶质母细胞瘤组织病理学特征119例;平均年龄,55岁)。继发性胶质母细胞瘤的诊断需要至少两次活检,以及从低级别或间变性星形细胞瘤进展的临床和组织学证据(30 例;平均年龄,39 岁)。DNA序列分析显示,p53突变在原发性胶质母细胞瘤中很少见(11%),而继发性胶质母细胞瘤的p53突变发生率较高(67%),其中90%在第一次活检中已经存在。p53蛋白积累(对PAb 1801的核免疫反应性)在原发性胶质母细胞(37%)中也低于在继发性胶质母细胞中(97%)。相比之下,EGF受体的免疫反应性在原发性胶质母细胞中占主导地位(63%),但在继发性胶质母细胞中很少见(10%)。49 例胶质母细胞瘤中只有 1 例显示 EGFR 过表达和 ap53 突变。这些数据表明,EGF受体的过表达和p53肿瘤抑制基因的突变是相互排斥的事件,定义了胶质母细胞瘤进化中的两种不同遗传途径,作为共同的表型末端

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号